DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market ...

Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic ...

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of 24.64% and 68.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...

Analysts anticipate Aligos Therapeutics to report an earnings per share (EPS) of $-2.97. Anticipation surrounds Aligos ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of Viking Therapeutics (NASDAQ: VKTX) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts. Seedhouse doesn't beat around the bush: "Our thesis is ...

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate RAPT Therapeutics, Inc. before investing. In this article, we go over a few key ...

--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7 ...

To put the 22.3% overall survival data in perspective, Keytruda’s various indications in first-line NSCLC are mostly based on 30%-plus reductions in the risk of death versus control arms. The ...